Weingärtner L, Sitka U, Patsch R, Richter I, Thiemann H H
Arzneimittelforschung. 1979;29(12a):1952-4.
This pharmacokinetic study involved school children who were treated with 6-[(R)-2-(2-oxo-imidazolidine-1-carboxamido)-2-phenyl-acetamido]-penicillanic acid sodium walt (azlocillin, Securopen) at doses of 50 mg/kg bodyweight or 75 mg/kg body weight i.v. Kinetics of the first order were found for the concentrations measured at the same time, being proportionate to the administered dose, while there was no dose dependence for the relative distribution volume. The elimination half-life was about 55 min. In 25 children of different age who had to undergo bronchoscopy for diagnositic and therapeutic reasons, the azlocillin concentrations in the bronchial secretions were measured 1 h and 4 h after the administration of 75 mg/kg quantity of bronchial secretion was obtained, azlocillin concentrations of 30 - 240 microgram/g were found. Measurements of azlocillin concentration in the bronchial secretion and in the serum, which were made at the same time, did not show any correlation.
这项药代动力学研究涉及学龄儿童,他们接受了静脉注射剂量为50mg/kg体重或75mg/kg体重的6-[(R)-2-(2-氧代-咪唑烷-1-甲酰胺基)-2-苯基-乙酰胺基]-青霉烷酸钠盐(阿洛西林,苯咪唑青霉素)治疗。同时测得的浓度呈现一级动力学,与给药剂量成正比,而相对分布容积不存在剂量依赖性。消除半衰期约为55分钟。在25名因诊断和治疗原因必须接受支气管镜检查的不同年龄段儿童中,在给予75mg/kg剂量1小时和4小时后测量支气管分泌物中的阿洛西林浓度,获得支气管分泌物量,发现阿洛西林浓度为30 - 240微克/克。同时在支气管分泌物和血清中进行的阿洛西林浓度测量未显示出任何相关性。